by McKesson Ventures | May 19, 2020 | Portfolio News
Aetion has signed a research collaboration agreement with the U.S. Food and Drug Administration to use real-world data to advance the understanding of and response to coronavirus disease (COVID-19). The research will support the FDA’s objectives to explore the natural...
by McKesson Ventures | May 12, 2020 | Portfolio News
In response to the COVID-19 pandemic, the HLTH Matters Blog Series will be interviewing experts from across the health ecosystem to bring timely facts and updates to the HLTH community. A post written by Aetion CEO Carolyn Magill details the role of real-world...
by McKesson Ventures | May 8, 2020 | Portfolio News
Aetion has issued a call for the FDA to implement a cloud-based real-world evidence (RWE) platform with robust data governance so that users can do data queries, archiving, access, and aggregation. Such a system, the company says, could help avoid unnecessary data...
by McKesson Ventures | Jan 9, 2020 | Portfolio News
Aetion and HealthVerity have announced a new partnership to streamline and accelerate access to HealthVerity’s expansive and diverse data sources and data preparation services for research on the Aetion Evidence Platform. Combining HealthVerity’s real-world data...
by McKesson Ventures | Oct 16, 2019 | Portfolio News
Aetion and McKesson have announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research. The goal of the collaboration is to benefit patients, regulators, the biopharma industry, and payers; it will provide...
